Acutaas Chemicals Ltd (NSE: ACUTAAS, BSE: 543349) is a Surat, Gujarat-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹32,068 Cr, it ranks #273 by market cap among the 6,197 Indian listed companies on FinBizNet, and #14 of 86 in Medicinal Chemicals and Botanical Products. At ₹4,055.00 (as of 16 Nov 2026), the share price is 1.8% below its 52-week high of ₹4,130.00 and 153.0% above its 52-week low of ₹1,602.50. The share price is up 128.8% over one year and up 29.8% over three months.
| Current Price | ₹4,055.00 |
|---|---|
| Market Cap | ₹32,068 Cr |
| NSE Symbol | ACUTAAS |
| BSE Code | 543349 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 92.2 |
| Return on Equity | 23.52% |
| Return on Assets | 15.74% |
| 52-Week Range | ₹1,602.50 – ₹4,130.00 |
| 1-Year Price Change | +128.8% |
| 3-Month Price Change | +29.8% |
| Beta (1Y) | 0.31 |
| Dividend Yield | 0.06% |
| Headquarters | Surat, Gujarat |
| Website | www.acutaas.com |
| Revenue | ₹437 Cr |
|---|---|
| Net Profit | ₹123 Cr |
| Net Margin | 28.2% |
| EPS (Basic) | ₹15.29 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Acutaas Chemicals Ltd reported revenue of ₹437 Cr in Q2 FY27, up 42.7% from ₹306 Cr in Q2 FY26 and up 32.5% from ₹330 Cr in Q1 FY27. It posted a net profit of ₹123 Cr for the quarter, against a net profit of ₹72 Cr in Q2 FY26 (up 71.4%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹207 Cr (Q1 FY26) to ₹437 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹437 Cr | ₹123 Cr | 28.2% |
| Q1 FY27 | ₹330 Cr | ₹75 Cr | 22.7% |
| Q4 FY26 | ₹433 Cr | ₹134 Cr | 31.0% |
| Q3 FY26 | ₹393 Cr | ₹106 Cr | 27.0% |
| Q2 FY26 | ₹306 Cr | ₹72 Cr | 23.5% |
| Q1 FY26 | ₹207 Cr | ₹44 Cr | 21.2% |
| Q4 FY25 | ₹308 Cr | ₹63 Cr | 20.3% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 32.66% of Acutaas Chemicals Ltd's shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 43.1% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Acutaas Chemicals Limited engages in the research and development, manufacture, and sale of pharmaceutical intermediates in India and internationally. The company offers pharma intermediates for use in regulated and generic active pharmaceutical ingredients for anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson’s, antidepressant, and anticoagulant applications. It also provides specialty chemicals for use in battery chemicals, personal care, agrochemicals, coatings, electronics, and industrial processes; photoresist chemicals to semiconductor applications; electrolyte additives for lithium battery cells; and parabens, methyl salicylate, and other commodity chemicals for cosmetics, agrochemicals, and fine chemicals. The company was formerly known as Ami Organics Limited and changed its name to Acutaas Chemicals Limited in May 2025. Acutaas Chemicals Limited was founded in 2004 and is based in Surat, India.
1. Custom Synthesis and Manufacturing of Speciality Chemicals-This segment engages in manufacturing pharmaceutical intermediates for active pharmaceutical ingredients. 2. NA-NA 3. NA-NA 4. NA-NA
1. Specialty Chemicals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Acutaas Chemicals Ltd | ₹32,068 Cr | 92.2 | 23.52% | ₹437 Cr | +128.8% |
Listed by market capitalisation. Ratios are shown for context only.
Acutaas Chemicals Ltd is trading at ₹4,055.00, with a market capitalisation of ₹32,068 Cr.
Acutaas Chemicals Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Acutaas Chemicals Ltd has a P/E of 92.2 and a return on equity of 23.52%.
Acutaas Chemicals Ltd is listed on the NSE under the symbol ACUTAAS and on the BSE under the scrip code 543349.
Acutaas Chemicals Ltd's share price is up 128.8% over one year and up 29.8% over three months. Its 52-week range is ₹1,602.50 to ₹4,130.00.
In Q2 FY27, Acutaas Chemicals Ltd reported revenue of ₹437 Cr and net profit of ₹123 Cr, with basic EPS of ₹15.29 (consolidated, parsed from the company's exchange filing).
Acutaas Chemicals Ltd reported revenue of ₹437 Cr in Q2 FY27, up 42.7% from ₹306 Cr in Q2 FY26 and up 32.5% from ₹330 Cr in Q1 FY27.
Promoters held 32.66% of Acutaas Chemicals Ltd's shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.